Roche
Building the base for current and future growth

London / Edinburgh roadshow
October 2006

Improved quality of the business

Building new franchises for a long-term sustainable business

Our priorities and outlook
Focus on differentiated medicines pays off
A young and growing portfolio

- CHF 1 billion or more
- CHF 2 billion or more
- CHF 4 billion or more

<table>
<thead>
<tr>
<th>2001</th>
<th>2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value drivers</td>
<td>6</td>
</tr>
<tr>
<td>Sales (CHF bn)</td>
<td>10</td>
</tr>
</tbody>
</table>

Improved quality of business over time
Year over year - despite Roaccutane and Rocephin

- Top 10 as % of pharma sales
- Key products as % of pharma sales

1 respective 10 leading products in each period
2 Avastin, Beniva, CellCept, Herceptin, MabThera, Rituxan, NeoRecormon, Epogin, Pegasy, Tarceva, Xeloda
Operating profit\(^1\)
*Continuous improvement each year*

<table>
<thead>
<tr>
<th>Year</th>
<th>Group continuing</th>
<th>Pharmaceuticals</th>
<th>Diagnostics</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>3.9</td>
<td>1.2</td>
<td>1.1</td>
</tr>
<tr>
<td>2002</td>
<td>4.9</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>2003</td>
<td>5.8</td>
<td>1.4</td>
<td>1.4</td>
</tr>
<tr>
<td>2004</td>
<td>7.0</td>
<td>1.7</td>
<td>1.7</td>
</tr>
<tr>
<td>2005</td>
<td>9.2</td>
<td>1.8</td>
<td>1.8</td>
</tr>
</tbody>
</table>

\(^1\) before exceptional items
Note: 2006 operating profits include expenses for equity-settled equity compensation plans (IFRS2); amortisation of actuarial gains/losses (IAS 19 revised) & the expected return on defined benefit plan assets and financing cost are removed from operating profits.

---

Improved quality of the business

Building new franchises for a long-term sustainable business

Our priorities and outlook
Roche key therapeutic areas
Current and future pillars of growth

As of September 30, 2006

Oncology: A rich phase III pipeline
Targeting main tumor types and use in early intervention
Roche in autoimmune diseases
Building a new therapeutic franchise

MabThera
- Launched in RA anti-TNF inadequate responders in US and EU
- Phase III in RA MTX inadequate responders on track, filing EU 2008
- Phase III for repeated treatment courses on track, filing EU 2008

Actemra
- Japanese phase III in DMARD inadequate responders met primary endpoints - filed in J
- Phase III in RA MTX IR, DMARD IR (RoW) on track, recruitment to complete by end 2006
- Global filing 2007

CellCept
- Phase III in Lupus Nephritis completed recruitment, filing 2007

MabThera
- Phase III in LN, PPMS, ANCA ass. vasculitis and SLE ongoing

Ocrelizumab
- Phase II trial met primary and secondary endpoints, to be presented at ACR ’06
- Phase III program to be finalized and initiated soon

R1503 (p38 kinase inhibitor)
- Phase II initiated in Q4’05

MabThera
- Phase II in RRMS met primary endpoints

Phase 1
- 7 compounds in development for autoimmune diseases

4 phase III projects
3 phase II projects

Roche in metabolic/ cardiovascular diseases
Major decision points within the near future

R1583 (GLP-1)
- Phase II data on immediate release formulation presented at ADA’06
- Start of phase II with sustained release formulation early 2007
- Filing post 2009

R1440 (GKA)
- Phase II started Q4’05
- First phase II data available 2007
- Filing 2009

R1658 (CETP inhibitor)
- First phase II completed – efficacy and safety confirmed
- Phase II safety trial ongoing
- Go/ No go decision for phase III in 2007
- Filing post 2009

3 phase II projects
4 phase I projects
Improved quality of the business over time

Building new franchises for a long term sustainable business

Our priorities and outlook

2006/7: Further strong newsflow expected

**Oncology: 4 phase III, 2 phase II, 3 phase I**

Avastin
- EU filing mCRC label extension
- Phase III data available AVOREN, CALGB 90206 (RCC)
- Final analysis AVAIL (NSCLC)
- Recruitment completed AVANT (adj. CC), AVADO (mBC)
- Start of phase III in adj. NSCLC, ovarian Ca

Xeloda
- Global filing mCRC label extension
- Final analysis mCRC 2nd line

MabThera
- Recruitment completed PRIMA (iNHL 1st line maint.)

Omnitarg
- Phase II data available
- R1492/R1584 (EpoD)
- Go/No go decision for phase III and II

R547 (CDK-inh)
- Go/No go decision for phase II

R1530 (MAI)
- Go/No go decision for phase II

**Anemia**

Mircera
- Phase III correction data to be presented at ASN’06

**Autoimmune diseases: 6 phase III, 1 phase II**

Actemra
- Final analysis of 4 phase III trials (RA)
- Recruitment completed LITHE (RA)

MabThera
- Recruitment completed SERENE and SUNRISE (RA)
- Phase II data (HERMES) in RRMS to be presented
- Go/No go decision for phase III in RRMS

CellCept
- Final analysis phase III Lupus Nephritis
- Final analysis phase III Myasthenia Gravis

Ocrelizumab
- Phase II (ACTION) to be presented at ACR ’06
- Start of phase III in RA

R1503 (p38 kinase inh)
- First phase II data available

**Metabolic/ Cardiovascular diseases: 2 phase II**

R1440 (GKA)
- First phase II data available

R1658 (CETP inh)
- Phase II completed
- Go/No go decision for phase III
2006/7: Further strong newsflow expected

Oncology: 4 phase III, 2 phase II, 3 phase I
- **Avastin**
  - EU filing mCRC label extension
  - Phase III data available AVOREN, CALGB 90206 (RCC)
  - Final analysis AVALIR (NSCLC)
  - Recruitment completed AVANT (adj. CC), AVADO (mBC)
  - Start of phase III in adj. NSCLC, ovarian Ca
- **Xeloda**
  - Global filing mCRC
  - Final analysis mCRC 2nd line

Autoimmune diseases: 6 phase III, 1 phase II
- **Actemra**
  - Final analysis of 4 phase III trials (RA)
  - Recruitment completed LITHE (RA)
- **MabThera**
  - Recruitment completed SERENE and SUNRISE (RA)
  - Phase II data (HERMES) in RRMS to be presented
  - Go/No go decision for phase III in RRMS
- **R1492/R1584 (EpoD)**
  - Go/No go decision for phase III
- **R547 (CDK-inh)**
  - Go/No go decision for phase II
- **R1530 (MAI)**
  - Go/No go decision for phase II

Autoimmune diseases: 6 phase III, 1 phase II
- **Mircera**
  - Phase III correction data to be presented at ASN’06

To be completed until mid ’07:

10 phase III projects

5 phase II projects

Our priorities

*Take actions now when there still is time*
Low generic risk
Long-term sustainable business

Sales erosion due to generisation (% of 2004 sales)

Source: citigroup

Roche: unique geographic risk diversification

USA  (Greater) Europe  Japan  Asia China  Latin America

Roche: unique “pillars of value” risk diversification

Tamiflu  Boniva  Actemra  Avastin in CRC
Herceptin  Tarceva  Xeloda  NeoRecormon
Pegasys  MabThera in RA  CellCept  Diabetes Care
Immuno-Diagnostics  MabThera  Molecular Diagnostics

Mircera  Avastin in NSCLC  Avastin in BC  JTT-705 (R1658)  GLP-1 (R1583)